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Abstract
The significance and diagnostic value of semen analysis in chronic bacterial prostatitis has been extensively debated 
and remains controversial.  To investigate the diagnostic relevance of semen culture in the bacteriological workup of 
prostatitis patients, we retrospectively analyzed a clinical database of 696 symptomatic patients.  All patients were 
routinely subjected to a four-glass test, followed by semen culture and analysis.  This allowed to dissect from the 
database three different diagnostic scenarios, and to compare the ‘two-glass’ pre-/post- massage test and the standard 
‘four-glass’ test with a ‘five-glass’ test (four-glass plus post-VB3 semen culture).  The ‘five-glass’ test showed 3.6- or 
6.5-fold increases in relative sensitivity and lesser reductions (–13.2% or –14.7%) in relative specificity for traditional 
uropathogens (TUs) compared with the four-glass or two-glass test, respectively.  The area under the ROC curve and 
Jouden’s index were increased, whereas positive and negative likelihood ratios were lower than comparators, indicating 
that the ‘five-glass’ assay may be superior in confirming the negative outcome of both standard tests.  The five-, four-, and 
two-glass tests detected TUs (Enterobacteriaceae, Enterococci, etc.) in 120, 33, and 20 patients and unusual pathogens 
(Streptococci, other Gram-positive species, Mycoplasmata, and others) in 130, 56, and 45 patients, respectively.  When 
patients were subjected to pharmacological treatment, including a combination of a fluoroquinolone and a macrolide, no 
differences in eradication rates were observed between groups diagnosed with different tests, irrespective of pathogen 
category.  Eradication was associated with long-term sign/symptom remission; no significant intergroup differences in 
sign/symptom scores were observed throughout a 24-month off-therapy follow-up period.  In conclusion, our data support 
the usefulness of semen analysis in the diagnostic workup of prostatitis patients when this test is used to complement the 
four-glass Meares and Stamey test.  Improvement of microbiological assays conveys important diagnostic and therapeutic 
implications.
Asian Journal of Andrology (2009) 11: 461–477.  doi: 10.1038/aja.2009.5;  published online  20 April 2009.
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1    Introduction
Chronic prostatitis (CP) syndromes have been 
traditionally classified as bacterial or abacterial [1]. 
Chronic bacterial prostatitis (CBP, category II, Na-
tional Institute of Diabetes and Digestive and Kidney 
Diseases [NIDDK] Chronic Prostatitis Workshop, 
1995) is diagnosed when lower urinary tract (LUT) 
cultures show an infected prostate gland as the focus 
of recurrent episodes of bacteriuria [2].  Prostatitis 
syndromes in which pathogens are not isolated fall into 
the CP/chronic pelvic pain syndrome class (CP/CPPS, 
category III, NIDDK), with inflammatory (IIIa) or non-
inflammatory (IIIb) variants, depending on white blood 
cell (WBC) counts in patients’ specimens.
The aetiology of abacterial prostatitis is mostly 
unknown; experts hypothesize neurological, psychological, 
anatomical, or immunological disorders as possible 
causes of this condition [3, 4].
In some cases, category III syndromes respond 
favourably to antibiotics.  For this reason, antibacterial 
agents (AA) are currently recommended for the empirical 
treatment of inflammatory CP/CPPS [5].  To explain the 
positive effect of AA in these cases, some experts indicate 
the intrinsic anti-inflammatory activity of quinolones as 
a possible determinant of patients’ response [6].  Others 
hypothesize an underlying infection by pathogens (including 
anaerobes; [7, 8]) that are not routinely searched for or 
detected by conventional techniques [9].
Since 1968, the four-glass assay according to 
Meares and Stamey [10, 11] has been considered the 
standard test for detection and localization of pathogens 
in the LUT.  About 10 years ago, a simplified two-glass 
test was proposed, based on the collection of sole pre-
prostatic massage (VB2) and post-massage (VB3) urine 
samples [12].
Some authors have suggested that segmented tests 
do not display sufficient sensitivity and may underes-
timate the prevalence of bacterial prostatitis cases, 
thus misdirecting the therapeutic approach to the 
disease [13, 14].  In addition to segmented tests, other 
procedures are adopted in the prostatitis diagnostic 
workup.  As semen contains diluted prostatic material 
(around 20%–30% of the total volume), together with 
material from the testes and other genital tract tissues, 
some authors have suggested the usefulness of semen 
analysis for the detection of prostatic pathogens. 
Mobley proposed culture of semen/total ejaculate 
about 30 years ago, but the efficacy of this assay is 
still debated [15].
Making reference to the results of a National In-
stitutes of Health-Chronic Prostatitis Collaborative 
Research Network (NIH-CPCRN) case-control study, 
Nickel [16] stated that no significant difference was 
shown in the detection of bacteria in the semen culture 
of CP/CPPS patients compared with asymptomatic 
subjects with no evidence of clinical CP/CPPS.  In a 
survey performed in 40 men with category II CBP due 
to Escherichia coli infection, Weidner and coworkers 
[17] demonstrated that semen cultures could identify 
significant bacteriospermia in only about 50% of 
semen specimens from men with CBP.  For this reason, 
ejaculate culture has not been recommended as a first-
line diagnostic assay in men with suspected CBP [18, 
19].  However, semen analysis has been associated 
with the standard four-glass assay for the detection 
of pathogenic bacteria and inflammatory leukocytes 
in important clinical studies performed by the NIH-
CPCRN [20].
Recently, Budía and coworkers [13] have published 
the results of a study performed on 895 patients who met 
the consensus criteria for clinical CP/CPPS, showing that 
semen has higher sensitivity than an expressed prostatic 
secretion (EPS) sample for the diagnosis of CBP.  Thus, 
culture and microbiological analysis of semen might 
increase the number of patients diagnosed with bacterial 
disease and decrease the number of subjects classified by 
exclusion into category III CP/CPPS.
Currently, semen culture and analysis has been 
indicated as ‘optional’ by the consensus meeting of the 
NIH-CPCRN (Chantilly, VA, USA, 26 March 2002; 
[21]) and has been ‘recommended in selected patients’ 
by the International Giessen Consensus (Giessen, 
Germany, September 2002; [21]).
In the context of published recommendations for the 
evaluation of patients with prostatitis, Nickel [21] stated 
that although semen analysis and culture do increase the 
number of patients placed in category II, the importance 
and relevance of this finding was unknown, because no 
study showed a significant symptomatic improvement 
in patients with demonstrated positive semen cultures 
when treated with antibiotics.
To address these issues, at least in part, we performed 
a retrospective survey on a database of over 900 patients 
from a single hospital.  The results of this study suggest that 
semen culture may complement the existing LUT segmented 
tests to enhance the sensitivity of microbiological 
analysis in symptomatic prostatitis patients.
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2     Patients and methods
The data presented in this study are the result of 
a retrospective survey on patients who underwent 
the non-experimental, diagnostic, and therapeutic 
protocols routinely adopted in our clinical setting 
between the years 2000 and 2006; these protocols 
were based on internationally recommended diagnostic 
and therapeutic algorithms.  Patients provided written 
consent to processing and anonymous publication 
of their clinical data.  According to Italian bylaws 
(Determinazione AIFA 20/3/2008, GU 76, 31/3/2008), 
the Ethical Committee of the Principal Investigator’s 
hospital was notified of the protocol describing the 
current observational study.
2.1  Study design, inclusion criteria, and diagnostic 
procedures
The present study is based on a retrospective ana-
ly sis of a database of over 900 patients who were 
diagnosed in a single primary care urological centre 
specializing in the treatment of prostatitis syndromes.
Patients between 20 and 59 years old were included 
in this study if they showed signs and symptoms of 
category II CBP or category III CP/CPPS at the first 
visit, according to the NIH criteria (NIDDK Chronic 
Prostatitis Workshop, Bethesda, MD, USA, Dec 7–8, 
1995).  Symptoms should have been present for at 
least 3 months within the 6 months before the first 
visit.  Clinical diagnosis required at least one of the 
characteristic signs/symptoms of prostatitis (i.e., 
dysuria, perineal pain or discomfort, testicular pain, 
painful ejaculation, associated or not with urinary 
frequency, urinary urgency, hesitance at micturition, 
urinary retention, or decreased urinary stream, prostate 
abnormality and/or asymmetry at digital rectal exami-
nation [DRE]).
Patients with any of the following conditions 
were not considered for this study: category I acute 
bacterial prostatitis; urethral discharge; Chlamydia; 
therapy with AA or other medications effective at 
the prostatic level within a 90-day period before 
entering the study; renal/hepatic/cardiac insufficiency; 
indwelling catheters; cystostomy; ureterostomy; 
previous prostatic or pelvic surgery; or neoplasia.  To 
reduce the confounding role of frank hyperplasia in 
the evaluation of voiding symptoms, life quality, and 
therapy outcomes, we excluded prostatitis patients 
presenting a prostatic enlargement exceeding 40 mL.
Database analysis allowed the identification of a 
cohort of 696 patients who met the above-mentioned 
criteria.
Published recommendations and internationally 
acknowledged guidelines were followed in the diagnosis 
of prostatitis [21].  Examination of history included 
a review of past and present symptoms, focusing on 
previous genitourinary diseases and infections, and 
on past and present medications.  The severity of 
CP symptoms was scored using an Italian validated 
translation of the NIH Chronic Prostatitis Symptom 
Index (NIH-CPSI) [22].  The physical examination 
included complete abdominal examination, focusing 
on the external genitalia and perineum.  Consistency 
and irregularity of the prostate gland were evaluated 
by DRE.  Pelvic and transrectal ultrasound was used 
for prostatic and bladder diagnostic imaging.  Urine 
peak flow rate (Qmax), percent bladder voided volume 
(% BVV), and post-micturition residual urine (by 
sovrapubic ultrasound) were measured in all patients.
Microbiological tests included, sequentially, (i) 
pre-VB1 urethral swab analysis and culture, followed 
by (ii) a four-glass LUT segmented localization test 
according to Meares and Stamey [10] and (iii) post-
VB3 semen analysis and culture.  Before each test, 
patients were required to cleanse thoroughly their hands 
and glans penis with an antiseptic soap.  The samples were 
tested for the presence and load of traditional uropathogens 
(TUs; Pseudomonas aeruginosa, Klebsiella spp., Proteus 
spp., E. coli, other members of the Enterobacteriaceae 
family, Enterococcus faecalis, Staphylococcus aureus) [23] 
and ‘unusual pathogens’ (UPs; definition by Skerk et al. 
[24]): Streptococcus spp., Haemophylus spp., Citrobacter 
spp., Coryneforms, Ureaplasma urealyticum, Mycoplasma 
spp., and others).  When a patient showed at least a 
TU together with an UP in the context of a multiple 
infection localized at the prostatic level, he was 
considered positive for class II CBP and placed in the 
TU group.  For diagnosis of bacterial infection of the 
prostate, colony counts in EPS/VB3 were required to 
be at least 10-fold greater than those assessed on VB1/
VB2.  In the case of detection of multiple pathogens in 
VB1, VB2, EPS, VB3, and semen samples, in order to 
exclude accidental contamination, localizations were 
confirmed by repeating the tests after 7 days.
Inflammatory WBCs were counted on four-
glass specimens and semen using the more stringent 
composite criteria (10 + in EPS, 5 + in VB3) described 
by Schaeffer et al. [20].
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2.2  Comparative analysis of microbiological diagnostic 
tests in CBP
2.2.1  Diagnostic scenarios
For comparative studies, the results of the above-
described microbiological tests were collected on 
a single database and used to dissect the following 
diagnostic scenarios:
—the VB2 and VB3 samples were used to diagnose 
bacterial prostatitis according to the two-glass pre-
massage and post-massage tests [12];
—the VB1, VB2, EPS, and VB3 samples were used 
to diagnose bacterial prostatitis according to the four-
glass Meares and Stamey test [10, 11];
—the VB1, VB2, EPS, VB3, and semen samples were 
used for pathogen detection within a complemented 
assay denominated ‘five-glass test’.
2.2.2  Comparative parameters
Comparison between diagnostic assays is typically 
performed by calculating the sensitivity (Se) and 
specificity (Sp) of ‘competing’ tests.  In a published 
report describing the results of a comparative analysis 
between segmented tests for diagnosis of CP/CPPS, 
2 × 2 contingency tables were used to compare the 
positivity/negativity of the four-glass test with the 
positivity/negativity of the two-glass test [25], and to 
calculate the relative sensitivity and specificity.  A similar 
approach was described by Zegarra Montes et al. [26]. 
We have adopted the same procedure in the current study 
by generating 2 × 2 tables to compare the five-glass test 
with the four-glass test or the two-glass test.
Variations in sensitivity imply a natural trade-off 
with the specificity of a given assay, thus hampering 
the comparison between diagnostic tests.  Therefore, 
grouping sensitivity and specificity within a single 
index or parameter, such as (i) the area under receiver 
operating characteristic curve (AUROCC), (ii) Youden’s 
index (j), or (iii) the likelihood ratio (LR), represents 
a more useful procedure for such a comparison.  In 
2000, Biggerstaff [27] described a graphic system 
of diagnostic accuracy allowing simple, immediate 
comparison between two dichotomous diagnostic 
tests by graphic visualization of the following three 
parameters:
—The AUROCC [28]: In a binary setting (e.g., in 
the case of dichotomous tests indicating a positive or 
negative outcome of an LUT segmented assay), the 
true positive rate (sensitivity) and the false positive rate 
(100-specificity) of the test define a single cutoff value 
on the receiver operating characteristic (ROC) graph, 
and the AUROCC at the cutoff point is simply the area 
under the trapezoid generated by the cutoff value on the 
ROC graph (i.e., the average between sensitivity and 
specificity ([Se+Sp]/2) [29].
—Youden’s index: This comprises specificity and 
sensitivity of a given assay in a single equation (j = 
Se−[1−Sp]).  ‘j’ ranges between 0 for a worthless test 
and 100 for an ideal test and is considered the best 
measure in terms of regret in a decision theoretical 
context [27].  In the Biggerstaff graph, j is the intercept 
on the vertical axis of a line with slope 1 (Figure 1), 
passing through the single cutoff point representing a 
given dichotomous test [27].
—Positive (LR+) and negative (LR–) likelihood 
ratios (LR+ = Se/[1−Sp]; LR– = [1−Se]/Sp; for 
definition see Zegarra Montes et al. [26]): These can 
also be extrapolated from the ROC graph and represent 
the slopes of the lines connecting a cutoff point to the 
origin of the axes (point [0, 0]) or to the point (100, 
100), respectively (Figure 1 [27]).
As indicated by Biggerstaff [27], LR+ and LR– 
lines relative to a ‘gold standard’ test divide the ROC 
plot into four areas: depending on the specific area in 
which a ‘competitor’ test is positioned in the chart, this 
can be classified as overall superior to the gold standard 
assay, and as overall inferior or superior for confirming 
the absence or the presence of a given disease [27]. 
A model graph showing these areas is reproduced in 
Figure 1.
2.3  Effect of pharmacological treatment in patients 
diagnosed with different localization tests
2.3.1  Study design
At time point T0, after complete clinical and microbio-
logical assessments, patients received a full course of 
combination pharmacological therapy.  On completion of 
treatment (one or two cycles), patients were subjected to 
a complete diagnostic protocol, including microbiological 
and clinical evaluations.  Patients showing microbiological 
persistence after 6 weeks of treatment were subjected to a 
second course of therapy, according to a protocol published 
earlier [30].  T1 was defined as the time point at which, 
after a first or second course of combination therapy, 
microbiological eradication was achieved, or, in the case 
of lack of eradication after a second cycle of therapy, 
pathogen persistence was observed.  At time points T2, 
T3, T4, T5 and T6–6, 12, 18, 24, and 30 months after 
time point T1, respectively–patients were subjected 
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to complete clinical evaluations (visits, instrumental 
analysis, questionnaires).  Microbiological analyses 
were repeated in patients showing symptom relapse 
during follow-up.
The same design was applied to the study performed 
on a subset of patients with negative four-glass cultures 
and positive semen localization of uropathogens, as 
described in Section 3.3.
2.3.2  Pharmacological treatment
Starting from time point T0, patients received an 
oral once-daily dose of 500 mg ciprofloxacin, associated 
with a single daily dose of 500 mg azithromycin, 
administered during the first three consecutive days 
at the beginning of each week of treatment with 
ciprofloxacin, as described earlier [30–32].  An alpha-
blocker (Alfuzosin ER, 10 mg day−1) was administered 
for voiding/obstructive signs and symptoms due to 
mechanical/inflammatory/proliferative alterations. 
Herbal extracts and supplements (Serenoa repens 340 
mg twice daily, lycopene, selenium) were added to the 
medication regime.
Combination therapy [30] included a daily dose 
of the alpha-adrenoceptor blocker alfuzosin (10 mg, 
extended-release formulation) [33] and a S. repens 
extract (640 mg day−1).  This therapeutic regimen was 
administered for 6 weeks to all patients.  In agreement 
with a published therapeutic algorithm [34], patients 
were treated with the alpha-blocker for the first 6 months 
of the follow-up period (time frame: T1–T2), to which 
the S. repens extract was also associated.
The same therapeutic scheme was administered to 
patients with negative four-glass cultures and positive 
semen localization of uropathogens (described in 
Section 3.3).
2.3.3  Response evaluation
Response was graded as follows, in agreement with 
the definitions and pathogen loads indicated by Naber 
et al. [35]:
—Eradication, defined as a causative organism absent 
(bacterial load: < 103 colony forming units [CFU] mL−1) 
after completion of therapy (T1 time point).
—Persistence, defined as a causative organism present 
(bacterial load: ≥ 103 CFU mL−1) after completion of 
therapy.
—Superinfection, defined as a causative organism 
eradicated (bacterial load: < 103 CFU mL−1), with the 
appearance of a different pathogen (bacterial load: ≥ 103 
CFU mL−1) after completion of therapy.
2.4  Statistics
χ2 test was used for contingency table and eradication 
rate comparisons.
Intragroup differences in NIH-CPSI questionnaire 
scores before/after therapy and during follow-up were 
analysed using Wilcoxon’s signed rank test.  Intragroup 
differences between Qmax or %BVV levels before/after 
therapy and during follow-up were measured using a 
paired, two-tailed t-test.  Intergroup differences in NIH-
CPSI scores were analysed using the Mann–Whitney/
Wilcoxon rank sum test.
Intergroup variance at single time points was ana-
lysed by ANOVA (Qmax, %BVV) or the Kruskal–Wallis 
test (NIH-CPSI scores).  The XLStatistics 5.71 program 
(©Rodney Carr; http://www.deakin.edu.au/~rodneyc/) 
was used for statistical analysis of data.
3    Results
3.1  Addition of semen cultures enhances the sensitivity 
of standard segmented tests for prostatic localization of 
Figure 1.  Likelihood ratio (LR) graph: regions of comparison 
[27].  The slopes (tangents) of the lines connecting the cutoff 
point of a ‘gold standard’ comparator test to points (0, 0) and (100, 
100) represent the LR+ and the LR–, respectively.  The LR+ and 
LR– lines divide the chart into four areas.  Depending on the 
position of a competitor test in these areas, it can be defined as 
overall superior to the gold standard, overall inferior, superior 
for confirming the absence of the disease under investigation, 
or superior for confirming the presence of the same disease. 
Youden’s index (j) is the intercept on the vertical axis of a line 
whose slope is 1, passing through the cutoff point.
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uropathogens
Retrospective analysis of bacteriological data in 696 
patients showing signs and symptoms of prostatitis and 
meeting restrictive selection criteria resulted in three 
different diagnostic scenarios: (i) a two-glass PPMT, 
in which only VB2 and VB3 samples were taken into 
account for uropathogen detection, (ii) a full four-glass 
test, comprising VB1, VB2, EPS, and VB3 samples, 
and (iii) a ‘five-glass’ test, joining a four-glass test with 
post-VB3 ejaculate culture and analysis.
The patients’ records were reviewed for detection 
of TUs or UPs.
Table 1 lists the number of patients with positive 
single or multiple localizations of TU or UP.
Table 2 compares the total number of patients showing 
positive or negative microbiological localizations on the 
basis of different diagnostic tests, stratified by class 
of pathogen.  A two-glass or four-glass test yielded 
20 (2.9%) or 33 (4.7%) positive localizations for 
TUs, respectively.  As a consequence, 676 (two-glass) 
and 663 (four-glass) patients of our cohort of 696 
symptomatic subjects were classified into the abacterial 
group.  With the five-glass test, the number of patients 
with positive cultures for TUs increased to 120 (17.2% 
of 696 patients) (i.e., 6-fold or 3.6-fold) compared with 
the two- or four-glass tests, respectively.  A similar 
trend was observed in the UP group.
Results of the χ2 test applied to 2 × 2 contingency 
tables comparing the five-glass test with the four-glass 
or two-glass tests (Table 3) served to reject the null 
hypothesis that differences in segmented tests would not 
affect test outcomes (P < 0.0001 for all comparisons).
Contingency tables allowed the calculation of relative 
sensitivity and specificity between five-glass and four-
glass or two-glass tests.  Table 4 shows that—for any class 
of pathogen—the five-glass test was characterized by a 
marked increase in sensitivity and a lesser decrease 
in specificity compared with both four- and two-glass 
tests.
Sensitivity and specificity allowed the calculation of 
three comparative parameters: the AUROCC, Youden’s 
index (j), and LR.
In the case of five-glass vs. four-glass comparison 
for detection of TUs, the AUROCC was 93.4 for the 
five-glass test and 63.7 for the four-glass test, and 
Youden’s index was 86.9 for the five-glass test and 27.5 
for the four-glass test (Figure 2, panel A).  When the 
five-glass test was compared with the two-glass test 
(panel B), the values of AUROCC were 90.9 and 57.3, 
respectively; j was 81.8 for the five-glass test and 14.6 
for the two-glass test.  Likelihood ratios of tests are also 
shown in Figure 2.  LR+ relative to two-glass or four-
glass tests was higher than the corresponding values 
shown by the five-glass test.  The LR– of the five-glass 
test was lower than the corresponding values shown by 
both the two-glass and the four-glass assays.  In this 
case, the five-glass test performs better than the four- 
or two-glass tests because an LR– closer to the unit 
indicates that a diagnostic assay cannot discriminate 
between diseased and non-diseased subjects showing a 
negative test.
Differences between test outcomes were highly 
significant in the case of UPs (Table 3; P < 0.0001 
for the null hypothesis for all comparisons, χ2 test), 
and the five-glass test showed increased sensitivity 
compared with the two standard comparators (Table 4). 
The parameters of grouping sensitivity and specificity 
(j, AUROCC) were also higher for the five-glass test 
compared with the four- or two-glass tests, and likelihood 
ratios followed a trend similar to that observed for the 
TU group (Figure 2, panels C, D).
3.2  Effect of pharmacological treatment of patients 
with positive localizations detected by a four-glass, a 
two-glass, or a five-glass assay
As shown in Table 2, the five-, four-, or two-glass 
tests allowed the localization of TUs in 120, 33, and 20 
symptomatic patients, respectively, whereas UPs were 
detected in 130, 56, and 45 patients, respectively.
The effect of a protocol of combination therapy 
including a fluoroquinolone and a macrolide, associated 
with an alpha-adrenoceptor blocker and a S. repens 
extract [30–32], was evaluated in these six groups of 
patients.  Table 5 lists the eradication rates stratified by 
pathogen class and diagnostic test.  The χ2 test revealed 
no differences between eradication rates (P > 0.8 for 
all comparisons), confirming the null hypothesis 
that different diagnostic tests would not affect the 
eradication rates of isolated pathogens.
Figure 4 shows the long-term effect of therapy on 
voiding signs (i.e., Qmax [panel A] and %BVV [panel B]) 
in patients showing TU or UP localizations by the five-, 
four-, or two-glass tests.  The proportion of drop-outs 
at late follow-up (T5–T6) was about 15% in all patient 
groups, irrespective of age, severity of the disease, 
diagnostic test, or pathogen.
Combination therapy induced a marked, significant 
improvement of both parameters in all studied groups 
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Table 1.  Microbiological isolates per patient, detected with five-, four-, or two-glass tests.
                                                                                                                          Number of patients with indicated isolate(s)
Traditional uropathogens                                                          Five-glass Four-glass Two-glass
Enterococcus spp. (single isolate): 48 7  4
    + E. coli   7 3  1
    + Proteus spp.   1 – –
    + Enterobacter spp.   1 – –
    + Streptococcus spp.   4 – –
    + Streptococcus spp. + C. albicans   1 – –
    + Ureaplasma urealyticum   2 – –
    + Haemophilus parainf.   1 – –
    + Staphylococcus spp. (coagulase-negative)   1 – –
    + Morganella morganii   2 – –
Escherichia coli 22 9 6
    + Streptococcus spp.   3 1 –
    + Streptococcus spp. + U. urealyticum   1 1 –
    + Streptococcus spp. + M. hominis   1 – –
    + M. hominis + U. urealyticum   1 – – 
Proteus spp.   8 5 4
    + E. faecalis + U. urealyticum   1 – –
Klebsiella spp.   4 2 2
    + C. albicans   1 – –
    + E. faecalis +E. coli   1 – –
    + E. faecalis +Citrobacter spp.   1 – –
    + E. faecalis + Corynebacterium spp.   1 1 1
Staphylococcus aureus   3 2 1
Pseudomonas aeruginosa   1 2 1
    + Corynebacterium spp.   1 – –
Enterobacter spp.   1 – –
    + Streptococcus spp.   1 – –
Total                                                                                              120                                      33                                        20
Unusual pathogens                                                                      Five-glass                             Four-glass                         Two-glass
    Streptococcus spp.                                                                           47                                      22                                        19
    + H. parainfluenzae   1 1  1
    + C. albicans   2 – – 
Ureaplasma urealyticum 21 7  7
    + H. parainfluenzae   1 1  1
    + C. albicans   2 – –
Haemophilus parainfluenzae 15 6  6
    + N. gonorrhoeae   1 1  1
Corynebacterium spp. 10 7  6
Staphylococcus spp. (coagulase-negative)   9 7 –
Morganella morganii   7 – –
Citrobacter spp.   4 1  1
Mycoplasma hominis + U. urealyticum   3 2  2
Gardnerella vaginalis   3 – –
Neisseria gonorrhoeae   – 1 –
Candida albicans   3 1  1
    Total                                                                                              130                                       56                                        45
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that showed good homogeneity of response and an 
absence of intergroup differences at each time point 
analysed (P > 0.1 [ANOVA] for all groups, divided or 
not by pathogen class, at all time points; Figure 3).
Similar results were obtained by analysing the 
three domains of the NIH-CPSI questionnaire: marked 
reductions in pain, voiding symptoms, and the impact 
of the disease on patients’ quality of life were observed 
at T1, were further enhanced at time point T2, and were 
extended throughout the entire 24-month follow-up 
period, up to time point T6 (Figure 4).  For all NIH-
CPSI scores, no intergroup differences were measured 
(P > 0.1, Kruskal–Wallis) for all groups at all time 
points, stratified or not by pathogen class (Figure 4).
3.3  Eradication of TUs localized in the semen sample of 
patients with a negative four-glass assay is associated 
with improvement of prostatitis signs and symptoms
To further evaluate the relevance of uropathogen 
localization in semen samples, we identified—within 
the population of 696 subjects described above—
patients showing positive semen cultures for TUs or 
UPs, but negative VB1, VB2, EPS, and VB3 samples. 
These symptomatic patients would have been classified 
by exclusion in the category III CP/CPPS group on the 
basis of a negative four-glass test [36].  
In these patients, analysis of WBC counts showed 
that 65.7% and 71.6% of patients with a TU (N = 74) or 
an UP (N = 87) in semen only, respectively, had more 
than 10 WBC per HPF in EPS or VB3 specimens.  No 
differences between these proportions were revealed 
by the χ2 test (P = 0.753), thus indicating similar 
inflammatory findings in both TU or UP groups.
From this patient population, we selected 64 
subjects showing a single positive localization of the 
five uropathogens most widely accepted as causative 
agents of category II CBP (i.e., E. coli, Pseudomonas 
aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, 
and Enterococcus faecalis) [37].
Patients were subjected to a 6-week course of 
Table 2.  Laboratory results in 696 symptomatic patients.
                                                                        Traditional uropathogens                                    Unusual pathogens
             Test  Five-glass Four-glass Two-glass Five-glass Four-glass Two-glass
Positive localization 120   33   20 130   56   45
Negative localization 576 663 676 566 640 651
Total 696 696 696 696 696 696
Prevalence, positive tests (%)             17.24                      4.74                   2.87                  18.67 8.04 6.46
Table 3.  2 × 2 contingency tables of positive and negative traditional uropathogen or unusual pathogen localization distribution when 
the 5-glass, 4-glass or 2-glass tests were applied to 696 patients with chronic prostatitis signs and symptoms.
Traditional uropathogens  Four-glass, negative Four-glass, positive Total
 Five-glass, negative  576   0 576
 Five-glass, positive   87 33 120
 Total 663 33 696
  Two-glass, negative Two-glass, positive Total
 Five-glass, negative  574   2 576
 Five-glass, positive 102 18 120
 Total 676 20 696
Unusual pathogens  Four-glass, negative Four-glass, positive Total
 Five-glass, negative  566   0 566
 Five-glass, positive   74 56 130
 Total 640 56 696
  Two-glass, negative Two-glass, positive Total
 Five-glass, negative  563   3 566
 Five-glass, positive   88 42 130
 Total 651 45 696
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combination pharmacological treatment, described in 
Section 2.  At time point T1, the AA were discontinued 
and in 46 patients showing microbiological eradication 
(72.2%) the two remaining drugs were administered 
for a period of 6 months.  In the remaining 18 cases, 
persistence of the causative pathogens was observed, 
and patients were subjected to a second cycle of 
combination therapy [30].  Therapy was effective in all 
18 patients who showed microbiological eradication. 
AA were then discontinued in this group, and the 
remaining drugs were administered for 6 months. 
At time point T2, 6 months after microbiological 
eradication, all 64 patients were off therapy for all 
drugs administered in the current protocol.
Figures 5 and 6 show the trends of Qmax, %BVV, 
and NIH-CPSI scores assessed before treatment (T0), 
at microbiological eradication (T1), and throughout the 
follow-up period (T2–T6).  Patients showing semen 
clearance underwent a marked improvement of all 
measured parameters and scores at the end of combination 
treatment with AA (T0–T1), extending throughout the 
entire follow-up period, beyond the 6-month therapy 
with alfuzosin and S. repens.
If patients were stratified according to the microbio-
logical outcome of combination therapy after a single 
cycle of treatment, the group (n = 46) showing pathogen 
eradication exhibited at T1 a mean pain score of 5.28 
± 2.71 compared with a value of 10.22 ± 4.27 at T0 
(−48.33%, P < 0.0001, Mann–Whitney/Wilcoxon).  The 
group of 18 patients showing persistence of causative 
pathogens after a first unsuccessful cycle of therapy 
exhibited a mean score of 6.83 ± 2.77 (score at T0 = 
11.16 ± 3.68), indicating a lesser pain reduction (−38.79%) 
than the former group.  The differences between pain 
scores in the two groups, which were not significant 
at T0 (P = 0.44, Mann–Whitney/Wilcoxon), became 
Table 4.  Comparison of relative sensitivity and specificity between the five-glass and the four-glass or two-glass tests.
  Traditional uropathogens Unusual pathogens χ2                 P-value
 Five-glass 100.0 100.0 
2.71 0.099
 Four-glass 27.5 43.1  
 Ratio 3.6 2.3                              –                        –
Sensitivity Five-glass 96.9 93.3 
5.52 0.018
 Two-glass 15.0 32.3  
 Ratio 6.5 2.9                              –                        –
 Five-glass 86.8 88.4 
0.008 0.930
 Four-glass 100.0 100.0  
 Ratio 0.9 0.8                              –                        –
Specificity Five-glass 84.9 86.5 
0.009 0.925
 Two-glass 99.6 99.5  
 Ratio 0.8 0.9                              –                        –
Table 5.  Eradication rates after one or two cycles of therapy, stratified by class of pathogen and test.
                                                                       Traditional uropathogens                                        Unusual pathogens
Test  Five-glass Four-glass Two-glass Five-glass Four-glass Two-glass
Eradication after 1 cycle    90 (75) 27 (81.8) 17 (85) 105 (80.7) 46 (82.1) 37 (82.2)
   of treatment (%)
Eradication after 2 cycles   22 (73.3)   5 (83.3)   3 (100)   21 (84)   9 (100)   7 (100)
   of treatment (% of persistent cases)
Total eradicated patients  112 (93.3) 32 (96.9) 20 (100) 126 (96.9) 55 (98.2) 44 (97.7)
   (% of total patients)
Total patients 120 33 20 130 56 45
χ2 0.018a  0.005b 0.04c 0.003a  0.001b 0.002c
P-value 0.89a 0.93b 0.84c 0.95a 0.97b 0.98c
aFive-glass vs. Four-glass, bFour-glass vs. Two-glass,  cFive-glass vs. Two-glass.
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significant after a single cycle of therapy (P = 0.044, 
Mann–Whitney/Wilcoxon), and lost significance when 
semen bacterial clearance was achieved in both groups 
(P = 0.13, Mann–Whitney/Wilcoxon).  No differences 
were recorded between the two groups when Qmax, 
%BVV, and NIH-CPSI voiding and life quality scores 
were compared (data not shown).
4    Discussion
Some authors have proposed that failure to detect 
bacterial infection in a number of prostatitis patients 
responding symptomatically to antibacterial treatment 
is because of the insufficient sensitivity of currently 
available LUT segmented tests [13].  Recently, a 
number of published studies focused on semen culture 
and analysis in CP patients [13, 26, 38, 39].  These 
reports demonstrated the efficacy of semen analysis in 
detecting pathogens that cause CBP.  However, with 
one exception, Reference [39], in these studies semen 
analysis was investigated as an alternative to prostatic 
massage in the context of a modified four-glass test 
Figure 2.  Likelihood ratio graphs comparing the four-glass Meares and Stamey test with the five-glass test and the two-glass PPMT 
with the five-glass test for the detection of traditional uropathogens or unusual pathogens. AUROCC, area under receiver operator 
characteristic curve; j, Youden’s Index; LR+, likelihood ratio for a positive test; LR–, likelihood ratio for a negative test.
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Figure 3.  Voiding parameters in symptomatic patients showing positive localizations of traditional uropathogens (TU) or unusual 
pathogens (UP) using the five-glass (black bars), four-glass (white bars), or two-glass (shaded bars) tests.  Patients were subjected to 
one or two cycles of combination therapy with ciprofloxacin, azithromycin, alfuzosin, and S. repens.  At microbiological eradication (time 
point T1), antibacterial agents were suspended and the remaining drugs were continued for a period of 6 months (T1–T2).  The follow-
up at the end of therapy was extended for 24 months, up to time point T6.  (A): Time course of urine peak flow rate (Qmax).  aP < 0.0001 
vs. T0; bP = 0.046 vs. T1.  Paired t-test.  Intergroup differences at each time point (ANOVA): P > 0.1 (TU and UP together); P > 0.1 (TU 
only); P > 0.1 (UP only).  (B): Time course of post-micturition percent bladder voided volume (% BVV).  aP < 0.0001 vs. T0; bP = 0.005 
vs. T0; cP = 0.01 vs. T0.  Paired t-test.  Intergroup differences at each time point (ANOVA): P > 0.1 (TU and UP together); P > 0.1 (TU 
only); P > 0.1 (UP only).
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Figure 4.  Pain, voiding, and life quality impact domains of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-
CPSI) assessed in patients showing positive localizations of traditional uropathogens (TU) or unusual pathogens (UP) using the five-
glass (black bars), four-glass (white bars), or two-glass (shaded bars) tests.  Patients were subjected to one or two cycles of combination 
therapy with ciprofloxacin, azithromycin, alfuzosin, and S. repens.  At T1 antibacterial agents were suspended and the remaining drugs 
were continued for a period of 6 months (T1–T2). The follow-up at the end of therapy was extended for 24 months (T6).  (A): aP < 
0.0001 vs. T0; bP < 0.001 vs. T1; cP = 0.00016 vs. T1; dP = 0.00019 vs. T1; eP = 0.091 vs. T1; fP = 0.07 vs. T1.  Wilcoxon signed rank 
test. Intergroup differences at each time point: P > 0.1 (TU and UP together); P > 0.1 (TU only); P > 0.1 (UP only).  Kruskal–Wallis 
test.  (B): aP < 0.0001 vs. T0; bP < 0.0001 vs. T1; cP = 0.0008 vs. T1; dP = 0.004 vs. T1; eP = 0.0003 vs. T1; fP = 0.89 vs. T1; gP = 0.83 
vs. T1.  Wilcoxon signed rank test. Intergroup differences at each time point: P > 0.1 (TU and UP together); P > 0.1 (TU only); P > 0.1 
(UP only).  Kruskal–Wallis test.  (C): aP < 0.0001 vs. T0; bP = 0.002 vs. T0; cP < 0.0001 vs. T1; dP = 0.004 vs. T1; eP = 0.009 vs. T1. 
Wilcoxon signed rank test. Intergroup differences at each time point: P > 0.1 (TU and UP together); P > 0.1 (TU only); P > 0.1 (UP 
only).  Kruskal–Wallis test.
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[26] or as an alternative to traditional segmented tests 
as a whole [13].  Our study indicates that, rather than 
representing a diagnostic alternative, semen culture and 
analysis can complement traditional four- or two-glass 
assays to detect an increased number of pathogens.  As 
shown by Zegarra Montes and coworkers [26], when 
used alone, semen analysis may misdiagnose a fraction 
of symptomatic patients.  As EPS/VB3 cultures may 
in some cases evidence pathogens not detected in the 
ejaculate, we believe that a four-glass test and semen 
analysis should be combined in the framework of a 
sequential five-glass test.
In this context, collection of the ejaculate after 
the VB3 sample may be advantageous, because it can 
generate a washout of the prostate and thus complement 
the prostatic massage, especially in the absence of 
EPSs.  The contraction of prostatic stromal smooth 
muscle fibres during the emission phase of ejaculation 
may in fact provide a propulsive force facilitating the 
extrusion of prostatic material and pathogens, mobilized 
by the prostatic massage.  This is shown in Table 1: 
addition of semen to a four-glass test allowed the 
detection of largely increased numbers of Enterococcus 
spp., E. coli, Staphylococcus, and Streptococcus spp. 
isolates, in agreement with the findings of a CPCRN 
study [20].  
In their report, Zegarra Montes and coworkers [26] 
admitted that a limitation of their study was not having 
Figure 5.  Voiding parameters in 64 patients showing positive 
semen cultures for traditional uropathogens (TU) but negative 
VB1, VB2, EPS, and VB3 samples. Patients underwent one or 
two courses of combination pharmacological therapy, described 
under Patients and methods.  At microbiological eradication (T1), 
the antibacterial agents were discontinued and the remaining 
compounds were administered for a period of 6 months, up to 
time point T2.  (A): Urine peak flow rate (Qmax); T1 vs. T0, P = 
0.0022; T2 vs. T0, P = 0.00013.  (B): Bladder percent voided 
volume; T1 vs. T0, P = 0.0056; T2 vs. T0, P < 0.0001.  Paired 
t-test.
Figure 6.  National Institutes of Health Chronic Prostatitis 
Symptom Index (NIH-CPSI) scored in 64 patients showing 
positive semen cultures for uropathogens, but negative VB1, 
VB2, EPS, and VB3 samples (four-glass test).  (A): Values at T1 
and T2 are significantly different from T0 and T1, respectively (P 
< 0.0001 in both cases).  (B): T1 vs. T0, P = 0.00103; T2 vs. T1 
or T0, P < 0.0001.  (C): impact of the disease on patients’ quality 
of life; T1 vs. T0 and T2 vs. T1 or T0, P < 0.0001.  Wilcoxon 
signed rank test.
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followed the response of their symptomatic patients to 
antibiotic treatment.  Indeed, a relationship between the 
mere isolation of a pathogen and its actual causative 
role in prostatitis can be better defined by investigating 
the clinical evolution of the syndrome after eradication 
of the detected pathogen.
In this respect and within the limits of an observational 
study, we have shown that the increased population 
of patients showing positive localization by the five-
glass test responded to pharmacological treatment in a 
manner not statistically different from that of patients 
diagnosed by means of traditional segmented assays. 
Thus, symptomatic patients classified as affected by 
bacterial prostatitis based on the five-glass, four-glass, 
or two-glass assays showed homogeneous responses 
to therapy, irrespective of the pathogen class and 
diagnostic test adopted.  Such homogeneous response 
points to a common aetiology of the condition of all 
diagnosed patients (i.e., bacterial infection).
It is important to underline that the improvement 
of Qmax, %BVV, and CPSI scores was extended beyond 
the 6-month period of prolonged therapy with alpha-
blockers and S. repens extracts.  Therefore, sustained 
remission from signs and symptoms of CP cannot 
be attributed to the transient effect of these agents, 
but is more likely due to permanent eradication of 
the pathogens localized at the prostatic level by the 
different tests.  However, this does not exclude a role 
of these agents in rapid symptom relief, even before 
microbiological eradication.
The reliability of semen as a diagnostic sample 
is further supported by our subset analysis performed 
on patients showing uropathogens in semen but not 
in VB1, VB2, EPS, or VB3.  These symptomatic 
patients, who were negative to the Meares–Stamey 
test and should have been classified by exclusion into 
the CP/CPPS class, showed sustained remission by 
clinical prostatitis signs and symptoms at the end of 
antibacterial treatment and, importantly, long after 
suspension of alpha-blocker therapy.  Moreover, NIH-
CPSI scores in this cohort of patients suggest that 
eradication of uropathogens specifically localized in 
semen samples may be associated with pain reduction, 
but that this symptom persists when semen clearance 
fails, although voiding symptoms were improved in 
non-eradicated patients, probably thanks to the effect of 
alpha-adrenoceptor blockers.
In summary, our results confirm that standard tests 
may underestimate the number of patients showing a 
symptomatic bacterial infection at the prostatic level, 
because the five-glass test detected about fourfold or 
sixfold more TUs when compared with the four- or 
two-glass tests, respectively.  In several cases (n = 35), 
semen contained the same pathogens found in EPS/
VB3 samples and confirmed the localization evidenced 
by the standard tests and, hence, the diagnosis of type 
II CBP.  In other cases, semen analysis alone allowed 
localization of pathogens in symptomatic patients, 
which would have been classified into the category III 
CP/CPPS on the basis of negative results of the four-
glass test [36] (i.e., in 87 patients in the TU group and 
in 74 patients in the UP group).
Besides TUs or UPs investigated in the present 
study, other organisms that are not analysed in daily 
clinical and laboratory routine may represent important 
aetiological determinants of prostatic infection. 
Imirzalioglu et al. [40] have shown that innovative 
molecular and chromatography techniques, associated 
with bioinformatic analysis, may reveal fastidious and 
anaerobic bacteria that have been shown to represent an 
important fraction (around 22%) of causative pathogens 
in urinary tract infections.
Nevertheless, because infection by TUs was demon-
strated in only 17.2% of symptomatic patients by the 
five-glass procedure, our study confirms non-bacterial 
aetiology as the primary cause of CP syndromes.
Analysis of different diagnostic scenarios allowed 
us to build contingency tables and compare the relative 
sensitivity and specificity between five-glass and four-
glass or two-glass tests.  Table 4 shows that—for any 
class of pathogen—compared with either four- or two-
glass tests, the five-glass test was characterized by a 
marked increase in sensitivity, associated with a lesser 
decrease in specificity.
Increased sensitivity implies a natural trade-off 
with the specificity of a given test, thus hampering the 
comparison between diagnostic assays.  Therefore, 
grouping sensitivity and specificity within a single 
index or parameter, such as (i) the AUROCC, (ii) 
Youden’s index (j), or (iii) LR, represents a more 
appropriate approach to comparison of the tests.  The 
display system according to Biggerstaff [27], which 
includes grouping all these parameters in a single 
comparative graph, showed that the five-glass assay 
falls into the area classifying a test as superior to a 
standard comparator for "confirming the absence of 
disease" (Figure 3).  However, this classification is 
applied when sensitivity and specificity values are 
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calculated from 2 × 2 contingency tables comparing 
the positivity/negativity of a test with the presence 
or absence of disease [27].  As in our case–as shown 
by Nickel et al. [25] and Zegarra Montes et al. [26]–
comparison is made with positivity/negativity of a 
reference standard test, the five-glass assay may be 
appropriately described as "superior for confirming 
the negative outcome" of the comparator four-glass or 
two-glass test.  In our case, superiority is due to the 
lower LR− shown by the five-glass test, relative to 
both standard tests.  In other words, semen analysis can 
complement standard tests to increase their negative 
predictive value (NPV) (e.g., NPV5-glass = 0.99 vs. 
NPV2-glass = 0.86).  As the diagnosis of category III CP/
CPPS is based on exclusion of demonstrable prostatic 
infection [36], superiority of the five-glass test in 
confirming the negative outcomes of four- or two-glass 
tests may be interpreted in terms of an increased power 
in the discrimination between category II CBP and 
category III CP/CPPS.  The therapeutic implications of 
increased diagnostic power are of notable importance 
because enhanced accuracy in differential diagnosis 
between bacterial and abacterial prostatitis can greatly 
enhance the quality of therapeutic protocols, direct 
the choice of specific drugs for effective antibacterial 
therapy, decrease the need for empirical treatment, and 
reduce the emergence of chemoresistance caused by the 
inappropriate use of antibiotics.
Figure 3 shows that similar comparative patterns 
can be observed for TUs or UPs, mostly represented by 
Gram-positive bacteria and Mycoplasmata.  Discussing the 
lack of reproducibility of Gram-positive localizations in 
segmented tests, Krieger and coworkers [41] suggested 
that these bacteria might represent intermittently shed, 
non-pathogen organisms transiently colonizing the 
LUT.  Indeed, several authors suggest that lactobacilli, 
coryneforms, streptococci, or other Gram-positive 
bacteria may survive in the prostate as non-pathogenic 
commensals (reviewed in Reference [42]).  However, 
we and others have documented, in the past and also 
in this paper, that eradication of uncommon pathogens 
(mostly Gram-positive bacteria) in symptomatic 
patients is associated with remission of CP signs and 
symptoms in a manner not statistically different from 
the response of patients showing TU localization [32, 
37].  In particular, we have performed a comparative 
analysis of microbiological and clinical responses to the 
same combination therapy protocol described in this 
paper in 104 symptomatic patients showing evidence 
of prostatic infection by TUs or by UPs [32].  The TU 
and UP groups showed a good correlation between 
eradication rates and clinical success rates, supporting 
the view that organisms other than the traditionally 
recognized uropathogens may play a role in prostatitis 
[32].  This is in agreement with data more recently 
shown by Nickel and Xiang [37].
A major limitation of segmented tests is repre-
sented by the likelihood of urine or semen to collect 
contaminating urethral organisms.  In a key review 
article in 1981, Stamey [11] stated that EPS or ejacu-
late samples might contain such organisms, which 
can mislead the diagnosis of an infection at the 
prostatic level.  Indeed, the viscosity of semen and 
the mechanical force applied during masturbation 
may result in detachment from the urethral walls 
of organisms colonizing the more distal tract of the 
urethra.  In their context, Stamey’s observations were 
meant to stress the limitations of the VB1 sample 
in detecting the presence of urethral contaminants. 
To reduce ambiguity in the interpretation of EPS or 
semen cultures, Stamey [11] proposed to attempt 
urethral clearance with oral penicillin or nitrofurantoin 
prior to segmented tests.  In daily clinical practice, 
such a procedure is unlikely to be adopted and can 
be misleading, due to the increasing fraction of 
chemoresistant commensals and pathogens.  A urethral 
swab, sterilely collected before the emission of VB1, 
might be a reasonable alternative to complement VB1 
(under investigation), provided that swabs do not allow 
quantitative measurement of bacterial loads.
In conclusion, our data indicate that the presence 
of pathogens in semen is likely to be indicative of an 
underlying prostatic infection if semen is analysed in 
the frame of a complete five-glass test.  In this context, 
semen culture and analysis may represent an important 
component of the diagnostic workup in patients showing 
clinical signs and symptoms of CP.
The limits of our study lay in its retrospective, 
observational design.  From a database of patients 
subjected to a panel of microbiological assays, we 
simulated the diagnostic scenarios of different segmented 
tests.  Moreover, patients included in our treatment 
protocol showed signs and laboratory findings of CBP: 
thus, we do not know to what extent patients with 
CPPS without microbiological localization would have 
responded to combination therapy (this is currently 
under investigation).  Ideally, distinct groups of 
randomized patients should be subjected to different 
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segmented tests and to subsequent single-agent 
antibacterial treatment.
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